2026-05-01T10:37:55Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/109862025-03-21T10:11:48Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19617

00925njm 22002777a 4500 dc García-Romero, N author Palacín-Aliana, I author Madurga, R author Carrión-Navarro, J author Esteban-Rubio, Susana author Jiménez, B author Collazo, A author Pérez-Rodríguez, F author Ortiz de Mendivil, A author Fernández-Carballal, C author García-Duque, S author Diamantopoulos-Fernández, J author Belda-Iniesta, Cristobal author Prat-Acín, R author Calvo, E author Ayuso-Sacido, Angel author Sánchez-Gómez, Pilar author 2020-06-22 Glioblastoma (GBM) is one of the most aggressive and vascularized brain tumors in adults, with a median survival of 20.9 months. In newly diagnosed and recurrent GBM, bevacizumab demonstrated an increase in progression-free survival, but not in overall survival. We conducted an in silico analysis of VEGF expression, in a cohort of 1082 glioma patients. Then, to determine whether appropriate bevacizumab dose adjustment could increase the anti-angiogenic response, we used in vitro and in vivo GBM models. Additionally, we analyzed VEGFA expression in tissue, serum, and plasma in a cohort of GBM patients before and during bevacizumab treatment. We identified that 20% of primary GBM did not express VEGFA suggesting that these patients would probably not respond to bevacizumab therapy as we proved in vitro and in vivo. We found that a specific dose of bevacizumab calculated based on VEGFA expression levels increases the response to treatment in cell culture and serum samples from mice bearing GBM tumors. Additionally, in a cohort of GBM patients, we observed a correlation of VEGFA levels in serum, but not in plasma, with bevacizumab treatment performance. Our data suggest that bevacizumab dose adjustment could improve clinical outcomes in Glioblastoma treatment. BMC Med . 2020 Jun 22;18(1):142. 10.1186/s12916-020-01610-0 1741-7015 1741-7015 BMC medicine 32564774 http://hdl.handle.net/20.500.12105/10986 Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma.